The utility of platelet activation biomarkers in thrombotic microangiopathies
Primary thrombotic microangiopathies (TMAs) are observed in thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), while secondary TMAs have a wide range of etiologies. Early diagnosis and treatment of TMA are critical for patient well-being; however, distinguishing TTP from...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-05-01
|
| Series: | Platelets |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09537104.2022.2026912 |
| _version_ | 1797684173710819328 |
|---|---|
| author | Mohammad Al-Tamimi Jianlin Qiao Elizabeth E. Gardiner |
| author_facet | Mohammad Al-Tamimi Jianlin Qiao Elizabeth E. Gardiner |
| author_sort | Mohammad Al-Tamimi |
| collection | DOAJ |
| description | Primary thrombotic microangiopathies (TMAs) are observed in thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), while secondary TMAs have a wide range of etiologies. Early diagnosis and treatment of TMA are critical for patient well-being; however, distinguishing TTP from HUS on presentation is particularly challenging. Thrombocytopenia and platelet activation are central to different types of TMAs, thus limiting the utility of standard diagnostic approaches to evaluate the platelet function and hemostatic capacity. Alternative means of quantifying and monitoring changes to platelet activation and function are urgently needed. Activated platelets have been shown to interact with proteins of the complement and coagulation cascades and form part of inflammation processes engaged in TMA. Increased levels of platelet surface receptors as well as increased plasma levels of platelet-derived soluble proteins have been reported in TMAs. Elevated levels of platelet-leukocyte aggregates and platelet microparticles are also reported in different types of TMAs. Larger prospective evaluations of platelet activation markers in TMA using standardized assays, with comparison to cohorts of patients with thrombosis, coagulopathy, and thrombocytopenia, to evaluate the clinical usefulness of platelet markers in TMA are now needed. This review will summarize the current knowledge around platelet activation markers and critically evaluate their utility in diagnosis and prognosis of TMA patients. |
| first_indexed | 2024-03-12T00:25:43Z |
| format | Article |
| id | doaj.art-f73c4bb625e54cbf845a10ae4c4fd44c |
| institution | Directory Open Access Journal |
| issn | 0953-7104 1369-1635 |
| language | English |
| last_indexed | 2024-03-12T00:25:43Z |
| publishDate | 2022-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Platelets |
| spelling | doaj.art-f73c4bb625e54cbf845a10ae4c4fd44c2023-09-15T10:38:10ZengTaylor & Francis GroupPlatelets0953-71041369-16352022-05-0133450351110.1080/09537104.2022.20269122026912The utility of platelet activation biomarkers in thrombotic microangiopathiesMohammad Al-Tamimi0Jianlin Qiao1Elizabeth E. Gardiner2The Hashemite UniversityXuzhou Medical UniversityAustralian National UniversityPrimary thrombotic microangiopathies (TMAs) are observed in thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), while secondary TMAs have a wide range of etiologies. Early diagnosis and treatment of TMA are critical for patient well-being; however, distinguishing TTP from HUS on presentation is particularly challenging. Thrombocytopenia and platelet activation are central to different types of TMAs, thus limiting the utility of standard diagnostic approaches to evaluate the platelet function and hemostatic capacity. Alternative means of quantifying and monitoring changes to platelet activation and function are urgently needed. Activated platelets have been shown to interact with proteins of the complement and coagulation cascades and form part of inflammation processes engaged in TMA. Increased levels of platelet surface receptors as well as increased plasma levels of platelet-derived soluble proteins have been reported in TMAs. Elevated levels of platelet-leukocyte aggregates and platelet microparticles are also reported in different types of TMAs. Larger prospective evaluations of platelet activation markers in TMA using standardized assays, with comparison to cohorts of patients with thrombosis, coagulopathy, and thrombocytopenia, to evaluate the clinical usefulness of platelet markers in TMA are now needed. This review will summarize the current knowledge around platelet activation markers and critically evaluate their utility in diagnosis and prognosis of TMA patients.http://dx.doi.org/10.1080/09537104.2022.2026912hemolytic uremic syndrome (hus)plateletsthrombocytopeniathrombosisthrombotic microangiopathies (tmas)thrombotic thrombocytopenic purpura (ttp) |
| spellingShingle | Mohammad Al-Tamimi Jianlin Qiao Elizabeth E. Gardiner The utility of platelet activation biomarkers in thrombotic microangiopathies Platelets hemolytic uremic syndrome (hus) platelets thrombocytopenia thrombosis thrombotic microangiopathies (tmas) thrombotic thrombocytopenic purpura (ttp) |
| title | The utility of platelet activation biomarkers in thrombotic microangiopathies |
| title_full | The utility of platelet activation biomarkers in thrombotic microangiopathies |
| title_fullStr | The utility of platelet activation biomarkers in thrombotic microangiopathies |
| title_full_unstemmed | The utility of platelet activation biomarkers in thrombotic microangiopathies |
| title_short | The utility of platelet activation biomarkers in thrombotic microangiopathies |
| title_sort | utility of platelet activation biomarkers in thrombotic microangiopathies |
| topic | hemolytic uremic syndrome (hus) platelets thrombocytopenia thrombosis thrombotic microangiopathies (tmas) thrombotic thrombocytopenic purpura (ttp) |
| url | http://dx.doi.org/10.1080/09537104.2022.2026912 |
| work_keys_str_mv | AT mohammadaltamimi theutilityofplateletactivationbiomarkersinthromboticmicroangiopathies AT jianlinqiao theutilityofplateletactivationbiomarkersinthromboticmicroangiopathies AT elizabethegardiner theutilityofplateletactivationbiomarkersinthromboticmicroangiopathies AT mohammadaltamimi utilityofplateletactivationbiomarkersinthromboticmicroangiopathies AT jianlinqiao utilityofplateletactivationbiomarkersinthromboticmicroangiopathies AT elizabethegardiner utilityofplateletactivationbiomarkersinthromboticmicroangiopathies |